FT516

DRUG3 trials

Sponsors

Fate Therapeutics, Masonic Cancer Center, University of Minnesota

Conditions

Acute Myelogenous LeukemiaB-cell LymphomaCOVID-19Solid Tumor, Adult

Phase 1

FT516 in Subjects With Advanced Hematologic Malignancies

TerminatedNCT04023071

Fate TherapeuticsAcute Myelogenous Leukemia, B-cell Lymphoma

Start: 2019-10-04End: 2023-10-23Updated: 2023-10-26

Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia

CompletedNCT04363346

Masonic Cancer Center, University of MinnesotaCOVID-19

Start: 2020-05-14End: 2021-02-18Updated: 2022-04-05

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

TerminatedNCT04551885

Fate TherapeuticsSolid Tumor, Adult

Start: 2020-09-07End: 2023-08-11Updated: 2023-09-21

Related Papers

Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: a multicentre, open-label, phase 1 study.

2025-07-01

365 Oxygen levels found in bone marrow (5%) provide an optimal niche for the differentiation of induced-pluripotent stem cell-derived NK cells for the treatment of AML

Regular and Young Investigator Award Abstracts2023-10-31

Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).

Journal of Clinical Oncology2021-05-2029 citations